Catheter ablation for ventricular tachyarrhythmias in patients supported by continuous-flow left ventricular assist devices

Arthur R. Garan, Vivek Iyer, William Whang, Kanika P. Mody, Melana Yuzefpolskaya, Paolo C. Colombo, Rosie Te-Frey, Hiroo Takayama, Yoshifumi Naka, Hasan Garan, Ulrich P. Jorde, Nir Uriel

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Ventricular arrhythmias (VAs) are common after implantation of a left ventricular assist device (LVAD) and in a subset of patients may be refractory to medication. Morbidity from VA in this population includes right ventricular failure (RVF). We sought to evaluate the efficacy of catheter ablation for VA in patients with LVAD. A retrospective analysis of patients supported by continuous-flow LVAD referred for catheter ablation of ventricular tachycardia (VT) between 2008 and the present was performed. Seven patients were referred for VT ablation an average of 236 ± 292 days after LVAD implantation. Three patients (42.9%) developed RVF in the setting of intractable arrhythmias. A transfemoral approach was used for six patients (85.7%) and an epicardial for one patient (14.3%). The clinical VT was inducible and successfully ablated in six patients (85.7%). The location of these arrhythmias was apical in three cases (42.9%). A total of 13 VTs were ablated in seven patients. Although the majority had reduction in VA frequency, recurrent VAs were observed in six patients (85.7%). One patient (14.3%) experienced a bleeding complication after the procedure. For patients with a high VA burden after LVAD implantation, VT ablation is safe and feasible, but VA frequently recurs.

Original languageEnglish (US)
Pages (from-to)311-316
Number of pages6
JournalASAIO Journal
Volume60
Issue number3
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Left ventricular assist devices
Heart-Assist Devices
Catheter Ablation
Catheters
Ablation
Tachycardia
Cardiac Arrhythmias
Ventricular Tachycardia
Refractory materials

Keywords

  • ablation
  • Left ventricular assist device
  • ventricular tachycardia

ASJC Scopus subject areas

  • Biophysics
  • Biomaterials
  • Bioengineering
  • Biomedical Engineering
  • Medicine(all)

Cite this

Garan, A. R., Iyer, V., Whang, W., Mody, K. P., Yuzefpolskaya, M., Colombo, P. C., ... Uriel, N. (2014). Catheter ablation for ventricular tachyarrhythmias in patients supported by continuous-flow left ventricular assist devices. ASAIO Journal, 60(3), 311-316. https://doi.org/10.1097/MAT.0000000000000061

Catheter ablation for ventricular tachyarrhythmias in patients supported by continuous-flow left ventricular assist devices. / Garan, Arthur R.; Iyer, Vivek; Whang, William; Mody, Kanika P.; Yuzefpolskaya, Melana; Colombo, Paolo C.; Te-Frey, Rosie; Takayama, Hiroo; Naka, Yoshifumi; Garan, Hasan; Jorde, Ulrich P.; Uriel, Nir.

In: ASAIO Journal, Vol. 60, No. 3, 2014, p. 311-316.

Research output: Contribution to journalArticle

Garan, AR, Iyer, V, Whang, W, Mody, KP, Yuzefpolskaya, M, Colombo, PC, Te-Frey, R, Takayama, H, Naka, Y, Garan, H, Jorde, UP & Uriel, N 2014, 'Catheter ablation for ventricular tachyarrhythmias in patients supported by continuous-flow left ventricular assist devices', ASAIO Journal, vol. 60, no. 3, pp. 311-316. https://doi.org/10.1097/MAT.0000000000000061
Garan, Arthur R. ; Iyer, Vivek ; Whang, William ; Mody, Kanika P. ; Yuzefpolskaya, Melana ; Colombo, Paolo C. ; Te-Frey, Rosie ; Takayama, Hiroo ; Naka, Yoshifumi ; Garan, Hasan ; Jorde, Ulrich P. ; Uriel, Nir. / Catheter ablation for ventricular tachyarrhythmias in patients supported by continuous-flow left ventricular assist devices. In: ASAIO Journal. 2014 ; Vol. 60, No. 3. pp. 311-316.
@article{a577b49dfb2b48539b570a1deafa4aa8,
title = "Catheter ablation for ventricular tachyarrhythmias in patients supported by continuous-flow left ventricular assist devices",
abstract = "Ventricular arrhythmias (VAs) are common after implantation of a left ventricular assist device (LVAD) and in a subset of patients may be refractory to medication. Morbidity from VA in this population includes right ventricular failure (RVF). We sought to evaluate the efficacy of catheter ablation for VA in patients with LVAD. A retrospective analysis of patients supported by continuous-flow LVAD referred for catheter ablation of ventricular tachycardia (VT) between 2008 and the present was performed. Seven patients were referred for VT ablation an average of 236 ± 292 days after LVAD implantation. Three patients (42.9{\%}) developed RVF in the setting of intractable arrhythmias. A transfemoral approach was used for six patients (85.7{\%}) and an epicardial for one patient (14.3{\%}). The clinical VT was inducible and successfully ablated in six patients (85.7{\%}). The location of these arrhythmias was apical in three cases (42.9{\%}). A total of 13 VTs were ablated in seven patients. Although the majority had reduction in VA frequency, recurrent VAs were observed in six patients (85.7{\%}). One patient (14.3{\%}) experienced a bleeding complication after the procedure. For patients with a high VA burden after LVAD implantation, VT ablation is safe and feasible, but VA frequently recurs.",
keywords = "ablation, Left ventricular assist device, ventricular tachycardia",
author = "Garan, {Arthur R.} and Vivek Iyer and William Whang and Mody, {Kanika P.} and Melana Yuzefpolskaya and Colombo, {Paolo C.} and Rosie Te-Frey and Hiroo Takayama and Yoshifumi Naka and Hasan Garan and Jorde, {Ulrich P.} and Nir Uriel",
year = "2014",
doi = "10.1097/MAT.0000000000000061",
language = "English (US)",
volume = "60",
pages = "311--316",
journal = "ASAIO journal (American Society for Artificial Internal Organs : 1992)",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Catheter ablation for ventricular tachyarrhythmias in patients supported by continuous-flow left ventricular assist devices

AU - Garan, Arthur R.

AU - Iyer, Vivek

AU - Whang, William

AU - Mody, Kanika P.

AU - Yuzefpolskaya, Melana

AU - Colombo, Paolo C.

AU - Te-Frey, Rosie

AU - Takayama, Hiroo

AU - Naka, Yoshifumi

AU - Garan, Hasan

AU - Jorde, Ulrich P.

AU - Uriel, Nir

PY - 2014

Y1 - 2014

N2 - Ventricular arrhythmias (VAs) are common after implantation of a left ventricular assist device (LVAD) and in a subset of patients may be refractory to medication. Morbidity from VA in this population includes right ventricular failure (RVF). We sought to evaluate the efficacy of catheter ablation for VA in patients with LVAD. A retrospective analysis of patients supported by continuous-flow LVAD referred for catheter ablation of ventricular tachycardia (VT) between 2008 and the present was performed. Seven patients were referred for VT ablation an average of 236 ± 292 days after LVAD implantation. Three patients (42.9%) developed RVF in the setting of intractable arrhythmias. A transfemoral approach was used for six patients (85.7%) and an epicardial for one patient (14.3%). The clinical VT was inducible and successfully ablated in six patients (85.7%). The location of these arrhythmias was apical in three cases (42.9%). A total of 13 VTs were ablated in seven patients. Although the majority had reduction in VA frequency, recurrent VAs were observed in six patients (85.7%). One patient (14.3%) experienced a bleeding complication after the procedure. For patients with a high VA burden after LVAD implantation, VT ablation is safe and feasible, but VA frequently recurs.

AB - Ventricular arrhythmias (VAs) are common after implantation of a left ventricular assist device (LVAD) and in a subset of patients may be refractory to medication. Morbidity from VA in this population includes right ventricular failure (RVF). We sought to evaluate the efficacy of catheter ablation for VA in patients with LVAD. A retrospective analysis of patients supported by continuous-flow LVAD referred for catheter ablation of ventricular tachycardia (VT) between 2008 and the present was performed. Seven patients were referred for VT ablation an average of 236 ± 292 days after LVAD implantation. Three patients (42.9%) developed RVF in the setting of intractable arrhythmias. A transfemoral approach was used for six patients (85.7%) and an epicardial for one patient (14.3%). The clinical VT was inducible and successfully ablated in six patients (85.7%). The location of these arrhythmias was apical in three cases (42.9%). A total of 13 VTs were ablated in seven patients. Although the majority had reduction in VA frequency, recurrent VAs were observed in six patients (85.7%). One patient (14.3%) experienced a bleeding complication after the procedure. For patients with a high VA burden after LVAD implantation, VT ablation is safe and feasible, but VA frequently recurs.

KW - ablation

KW - Left ventricular assist device

KW - ventricular tachycardia

UR - http://www.scopus.com/inward/record.url?scp=84900398247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900398247&partnerID=8YFLogxK

U2 - 10.1097/MAT.0000000000000061

DO - 10.1097/MAT.0000000000000061

M3 - Article

VL - 60

SP - 311

EP - 316

JO - ASAIO journal (American Society for Artificial Internal Organs : 1992)

JF - ASAIO journal (American Society for Artificial Internal Organs : 1992)

SN - 1058-2916

IS - 3

ER -